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ABSTRACT
Objectives Quantitatively examine the content of National 
Health Service Health Check (NHSHC), patient–practitioner 
communication balance and differences when using 
QRISK2 versus JBS3 cardiovascular disease (CVD) risk 
calculators.
Design RIsk COmmunication in NHSHC was a qualitative 
study with quantitative process evaluation, comparing 
NHSHC using QRISK2 or JBS3. We present data from the 
quantitative process evaluation.
Setting and participants Twelve general practices in 
the West Midlands (England) conducted NHSHC using 
JBS3 or QRISK2 (6/group). Patients were eligible for 
NHSHC based on national criteria (aged 40–74, no existing 
cardiovascular- related diagnoses, not taking statins). 
Recruitment was stratified by patients’ age, gender and 
ethnicity.
Methods Video recordings of NHSHC were coded, 
second- by- second, to quantify who was speaking 
and what was being discussed. Outcomes included 
consultation duration, practitioner verbal dominance (ratio 
of practitioner:patient speaking time (pr:pt ratio)) and 
proportion of time discussing CVD risk, risk factors and 
risk management.
Results 173 video- recorded NHSHC were analysed (73 
QRISK, 100 JBS3). The sample was 51% women, 83% 
white British, with approximately equal proportions across 
age groups. NHSHC duration varied greatly (6.8–38.0 min). 
Most (60%) lasted less than 20 min. On average, CVD 
risk was discussed for less than 2 min (9.06%±4.30% of 
consultation time). There were indications that, compared 
with NHSHC using JBS3, those with QRISK2 involved less 
CVD risk discussion (JBS3 M=10.24%, CI: 8.01–12.48 vs 
QRISK2 M=7.44%, CI: 5.29–9.58) and were more verbally 
dominated by practitioners (pr:pt ratio JBS3 M=3.21%, CI: 
2.44–3.97 vs QRISK2=2.35%, CI: 1.89–2.81). The largest 
proportion of NHSHC time was spent discussing causal 
risk factors (M=37.54%, CI: 32.92–42.17).
Conclusions There was wide variation in NHSHC 
duration. Many were short and practitioner- dominated, 
with little time discussing CVD risk. JBS3 appears to 
extend CVD risk discussion and patient contribution. 
Qualitative examination of how it is used is necessary to 
fully understand the potential benefits of these differences.
Trial registration number ISRCTN10443908.
INTRODUCTION
Cardiovascular disease (CVD) accounts for 
over a quarter of UK deaths and costs the 
National Health Service (NHS) around 
£9 billion annually.1 As CVD mortality 
decreases in the UK, there is a high preva-
lence of people living with CVD.2 Prevention, 
therefore, remains a priority, for which the 
NHS Health Check (NHSHC) Programme is 
an important part.3 4 NHSHC aims to assess 
CVD risk factors among adults in England 
aged 40–74 years who are not known to 
have certain cardiovascular- related diseases.5 
It is the largest CVD risk identification and 
management programme of its kind glob-
ally, and has been linked with some increases 
in the detection of risk factors and chronic 
disease, and statin prescriptions,6 7 with mixed 
predictions of benefits from microsimulation 
studies.8 9
NHSHC consultations typically take place 
in primary care with a primary care nurse, 
and comprise: (a) assessing patients’ CVD 
risk, (b) communication of CVD risk, which 
should inform (c) discussion of CVD risk 
management through lifestyle or subse-
quent medical appointments or referrals. 
Strengths and limitations of this study
 ► Video recordings of National Health Service Health 
Check provided an objective record of practice 
across a range of general practices.
 ► Second- by- second coding was used to characterise 
the content of health checks that used either QRISK2 
or JBS3 cardiovascular disease risk calculators.
 ► The study was limited to 12 general practices in the 
West Midlands of England.
 ► Initial target sample size was not achieved.
 ► Qualitative data are necessary to provide further 
insight.
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The NHSHC competence framework specifies that prac-
titioners should understand CVD risk and be able to 
communicate to patients their CVD risk such that ‘the 
patient understands their level of risk’ (Public Health 
England,10 p21). This should lead to discussion with 
the patient about management of that risk through 
‘person- centred conversations about their own reasons 
for change’ (Public Health England,10 p21), using tech-
niques like motivational interviewing. This accords 
with the idea of shared decision- making, described 
as the pinnacle of patient- centred care (Barry and 
Edgman- Levitan).11 In shared decision making, health 
professionals and individuals work together to agree 
management or support, based on evidence and the 
patient’s preferences.12
To date, little is known about the nature or content of 
real- world NHSHC consultations. Evidence regarding 
what takes place in the consultations is mainly limited 
to qualitative data from retrospective interviews with 
patients and practitioners asked to recall and reflect on 
their experiences.13 Such data do have value. However, 
they do not present a complete understanding of the 
dynamics and interactions that can initiate subsequent 
actions or interventions (eg, referral of patients to effec-
tive lifestyle- support programmes, appropriate specialist 
referrals) that could lead to improved patient outcomes.
This paper reports the relative contributions of practi-
tioners and patients, and the time spent discussing CVD 
risk and risk management in NHSHC consultations. This 
is important to understand as lack of time is the barrier 
to shared decision- making, most frequently cited by 
practitioners and patients.14 Consultations in which the 
health professional and patient work together to iden-
tify risk- management strategies, taking evidence and 
patient preference into account,12 require more time 
than didactic encounters involving little patient involve-
ment.14 Studies of clinician–patient interactions have 
identified that short, clinician- dominated (or ‘paternal-
istic’) consultations, are less patient- centred and linked 
with low patient and clinician satisfaction,15–18 which in 
turn, have been linked with poorer patient outcomes, 
such as adherence to clinical recommendations and 
health- promoting behaviour.19 20 While there is some 
evidence that brief interventions of just a few minutes can 
contribute towards behavioural change,21 motivational 
interviewing, a technique recommended in NHSHC, may 
require 15 min or more to be effective.22 Pieterse et al14 
summarised the relatively modest literature that specifi-
cally links time with shared decision- making. The authors 
noted that health professionals often feel under time 
pressure. Time with patients is constrained by a schedule 
that determines the maximum appointment length, and 
the need to complete all clinical and administrative tasks. 
Hurried practitioners might interrupt the conversation23 
or present information too quickly or use inappropriate 
language, reducing the likelihood that information will 
be retained.14 For NHSHC, it is likely to be important 
that time is sufficient for a two- way interaction in which 
patients can be supported to develop their own CVD risk- 
management strategy.
Time is also likely to be an important consideration 
in communication of CVD risk in NHSHC. Cypher 
identified prerequisites of shared decision- making that 
included ‘accurate, impartial and comprehensible infor-
mation’ presented by a practitioner who is ‘proficient in 
communication and able to individualize data to a partic-
ular situation’ (Cypher,24 p1). All NHSHCs must involve 
assessment of CVD risk using QRISK (QRISK2 and, 
more recently, QRISK3).25 26 QRISK, which is embedded 
within primary care medical record software, provides a 
percentage risk of a CVD event in the next 10 years. This 
has to be communicated to patients for the NHSHC to be 
considered ‘complete’. It is integrated within the general 
practice electronic medical record software, so it can be 
calculated from pre- populated and new data. The score 
is then directly saved into the patient’s record. However, 
there are limitations with the QRISK score and how it is 
used. First, 10- year risk estimates, such as those presented 
by QRISK, have been criticised for being heavily influ-
enced by age and gender, thereby underestimating risk in 
younger adults and women, and not accounting for risk 
from other diseases as effectively as long- term (lifetime) 
estimates.27 28 Second, qualitative studies indicate limited 
practitioner and patient understanding of percentage 
CVD risk13 and that practitioners report difficulties in 
explaining percentage CVD risk.29–32 In turn, patients 
attending NHSHCs have been unable to recall being 
provided with a risk score or find it confusing.13
In 2014, the Joint British Societies recommendations 
on the prevention of CVD (JBS3) launched the JBS3 risk 
calculator. JBS3 has a primary focus on lifetime risk,27 
includes heart age33–35 and uses multiple visual displays 
to present risk (eg, Cates plot, image of a heart for heart 
age, visual analogue scales).36 It has also been designed 
to support communication of tailored information by 
allowing manipulation and, thus, demonstration of the 
effects of risk factor modification (eg, smoking cessa-
tion) on lifetime risk trajectory. There is some evidence 
that lifetime risk, as provided by JBS3, can identify raised 
CVD risk in some people that would not be picked up 
through conventional 10- year risk estimates (given within 
QRISK2);37 that heart age is more easily communicated 
to, and recalled by, patients;38 39 and that graphical 
displays can be preferable for promoting risk- reducing 
behaviour.40 Collectively, these attributes of JBS3 might 
accommodate a more extensive and higher quality inter-
action between patients and practitioners.33 36 However, a 
comparison of the relative benefits JBS3 and QRISK2 for 
communicating CVD risk in NHSHC has not been under-
taken. Given that practitioners currently have choices in 
CVD risk calculators, establishing their relative values is 
important, particularly with regards to knowing which 
approach best promotes communication that supports 
positive behavioural change.
In summary, NHSHC aims to assess CVD risk and to 
prompt minimisation of risks identified. To date, there 
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is insufficient knowledge about how NHSHCs are 
conducted, the time spent discussing CVD risk and its 
management, and the potential of alternative CVD risk 
calculators, like JBS3. RIsk COmmunication (RICO) in 
NHSHC is a large study of practitioner and patient percep-
tions and understanding of CVD risk when using the 
JBS3 or QRISK2 CVD risk calculators.41 Video- recording 
methods in RICO have provided the first objective data of 
real- world NHSHC, allowing for extensive qualitative and 
quantitative analysis. In this paper we present the quanti-
tative data, with three aims: (a) examine the time spent 
discussing CVD risk, risk factors and management in 
NHSHC consultations; (b) explore the level of patient–
practitioner communication balance; (c) compare a and 
b when NHSHCs are conducted using QRISK2 versus 
JBS3 CVD risk calculators.
METHOD
Study design
The RICO Study is a qualitative study with quantita-
tive process evaluation. A detailed description of the 
overall study, including sampling, recruitment and data 
collection is available.41 Here, we report a quantitative 
comparison of the content of video- recorded NHSHC 
consultations.
Patient and public involvement and Engagement
Our approach was informed by extensive patient and 
public involvement and engagement (PPIE). Engage-
ment with patient participation groups at three general 
practices on two occasions was used to gather opinion on 
the study concept and overall design, and subsequently, 
the methods and protocols, participants’ consent and 
debrief processes, and for the development of the coding 
framework. Four mock NHSHCs were used to test proto-
cols, such as camera placement and video recording. For 
ongoing involvement of patients, two patient representa-
tives sat on the Study Steering Committee and a virtual 
study patient group was established using a closed Face-
book group (>260 members).
Setting and general practice recruitment
Data were collected across 12 general practices in the 
West Midlands of England that already delivered NHSHC 
(January 2017–February 2019). Practices were recruited 
via the local Clinical Research Network. Six practice pairs, 
approximately matched by deprivation, were randomly 
assigned to one of two groups: QRISK2 (usual practice)—
practitioners continue to use QRISK2 to calculate CVD 
risk; JBS3 (intervention)—practitioners calculate the 
CVD risk using JBS3 following brief training about the 
platform (no training regarding risk communication was 
provided). To enable assessment of differences arising 
from JBS3 compared with QRISK2, as a minimum, those 
using JBS3 were asked to use the output screens showing: 
(a) heart age—estimate of heart age compared with 
someone of the same gender, ethnicity and risk factors 
at optimal levels; (b) healthy years—estimate of the age 
the patient can expect to reach without a CVD event (or 
event- free survival age). They were also asked to show 
patients the effect of intervention on one or more of 
the CVD risk metrics (eg, effect of smoking cessation on 
event- free survival age). A brief training video was created 
to guide clinicians (https://www. youtube. com/ watch? v= 
idecGzlwIc4& feature= youtu. be).
Participants and recruitment
Patients were those eligible for NHSHC based on national 
criteria. Thus people were excluded if they were outside of 
the target age range (40–74 years), had existing diagnoses 
for certain cardiovascular- related chronic conditions, 
took statins, had received an NHSHC in the last 5 years or 
were known to be at high risk of CVD.25 Within each prac-
tice, the list of eligible patients was stratified according to 
age, gender and ethnicity, and invitations were sent to a 
representative sample. Postal invitations were distributed 
and follow- up calls were made by practice staff.
Practitioners all worked within primary care (nine 
healthcare assistants (HCA), five practice nurses, one 
sister) and already undertook NHSHC as part of routine 
practice. The only exception was one HCA who was new 
to NHSHC delivery.
Data sources and processing
Participating practices were asked to video record 
NHSHCs using the allocated CVD risk calculator until 20 
useable consultations were recorded (with written permis-
sion from patients and practice consent). Video- recorded 
NHSHC consultations were the main data source. 
Recorded NHSHCs were viewed by two authors (LC and 
VAR) and the content of consultations was characterised 
using a second- by- second coding framework developed 
specifically for this study. The framework comprised 36 
items grouped into six categories: patient–practitioner 
communication, health check general (eg, collecting and 
inputting data), risk dialogue (eg, overall discussion of 
risk, 10- year risk score reference, heart age, patient ques-
tion on CVD risk), causal CVD risk factors (medical, life-
style), risk management (lifestyle intervention, medical 
intervention; online supplemental file 1). This allowed 
derivation of aggregate indicators for each consultation, 
to allow between- group comparisons for:
 ► Length of NHSHC.
 ► Time (absolute and proportion of consultation) 
discussing CVD risk, CVD risk factors (overall, lifestyle, 
medical) and risk management (lifestyle, medical).
 ► Practitioner dominance (ratio of practitioner:patient 
speaking time).
 ► Number and proportion of patients asking questions 
about CVD risk.
 ► Use of heart age, healthy years (event- free survival 
age) and risk score manipulation (as fidelity check in 
the JBS3 group).
As noted previously,41 the coding process and frame-
work development was iterative, using four mock 
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NHSHCs that were video recorded as part of PPIE. To 
reach consistency in approach, two authors (NJE and 
LC) coded mock NHSHCs by consensus. Author VAR 
then coded the same four consultations independently 
and Intraclass Correlation Coefficients (ICCs) demon-
strated excellent inter- rater reliability (ICCs from 0.968 
to 0.995). Once data collection had begun, NHSHC were 
coded by authors LC and VAR, with verification of 10% (2 
in every 20 independently coded) to mitigate the risk of 
coder drift throughout the study. ICCs ranged from 0.992 
to 0.999, indicating excellent inter- rater reliability.
Data were extracted from patients’ medical records on 
patients’ sex, age and ethnic background (classified as 
white British (WBRI) or black, Asian and minority ethnic 
(BAME)).
Sample size
The target sample size was 240 (120 per group). A sample 
size calculation undertaken for the desired between- 
group quantitative comparison estimated that 120 consul-
tations per group, six clusters per group with a two- tailed 
probability and alpha of 0.05, would provide statistical 
power of 0.8 to detect an effect size (r)=0.24 (small to 
medium effect). The overall number of eligible practices 
from which the clusters were chosen was 625 (based on 
number of general practices in the West Midlands).
Statistical methods
Following checks for normal distributions, QRISK2 and 
JBS3 groups were compared according to key variables. 
Confidence intervals (95% CIs) were calculated taking 
account of the nature of the sampling which was in clus-
ters; as usual, where the CIs of the two groups did not 
overlap, the groups were considered to differ significantly. 
Data processing and analysis were performed in SPSS 
V.26.
RESULTS
Participants
One hundred and seventy- five video- recorded NHSHCs 
were completed, of which 173 were included in anal-
ysis (QRISK=73; JBS3=100; 2 excluded for practitioner 
process error that invalidated the consultation). The 
sample comprised approximately equivalent proportions 
of men and women, and proportions in WBRI versus 
BAME groups that were representative of the geograph-
ical region (table 1). Average age of the JBS3 group 
(M=60.87; CI: 58.91–62.83) was higher than QRISK2 
(M=54.70, CI: 51.66–57.70), while mean 10- year CVD risk 
was slightly higher in the JBS3 group (M=9.71, CI: 7.85–
11.57) than the QRISK2 group (M=8.69, CI: 5.56–11.81).
Length of NHSHC consultations
Table 2 summarises the characteristics of NHSHC consul-
tations by group and overall. There was a wide range in 
consultation length, from just 6.8 to over 38 min, but the 
majority were between 15 and 20 min (figure 1). Consulta-
tions were only slightly shorter on average in the QRISK2 
compared with JBS3 group (with a relatively small effect 
size of 0.13).
Discussion of CVD risk
Overall, less than 10% of overall consultation time 
was devoted to CVD risk discussion, which equated to 
1.7±0.83 min. A higher proportion of consultation time 
was spent discussing CVD risk using JBS3 (equivalent 
to 2.1±0.82 min) compared with QRISK2 (equivalent 
Table 1 Participants’ characteristics
Total JBS3 QRISK Difference
n % n % n % r *
Age (years) 40–54 60 34.68 24 24.00 36 49.32 0.32
55–64 54 31.21 30 30.00 24 32.88
65–74 59 34.10 46 46.00 13 17.81
Total 173 100 73
Gender Male 86 49.71 49 49.00 37 50.68 0.05
Female 87 50.29 51 51.00 36 49.32
Total 173 100 73
Ethnicity† WBRI 144 83.24 81 81.00 63 86.30 0.07
BAME groups 29 16.76 19 19.00 10 13.70
Total 173 100 73
CVD risk category‡ Low 104 60.12 57 57.00 47 64.38 0.06
Medium–high 67 38.73 41 41.00 26 35.62
Total 171 98 73
*Effect size, r: where 0.1 is small, 0.3 is medium, 0.5 is large.
†Ethnicity: White British (WBRI); black, Asian and minority ethnic group (BAME).
‡Cardiovascular disease (CVD) risk categories: low is 10%, medium- high is ≥10%.
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to 1.31±0.63 min), with a medium effect size. Nearly all 
NHSHCs in both groups included reference to the 10- year 
percentage CVD risk score (94% vs 94.5%, r=0.01). The 
proportion of patients asking questions about CVD risk 
was higher in the JBS3 versus QRISK2 group (32.0% vs 
12.3%, r=0.23).
Within the JBS3 group, nearly all practitioners 
discussed heart age (100%) and healthy years (97%), and 
manipulated the risk score(s) to show the potential effect 
of intervention on risk (92%). This showed fidelity to 
the requested minimum use of JBS3 outputs. The use of 
heart age and risk manipulation was also evident in 52.1% 
and 21.9% of QRISK2 consultations, respectively. This is 
a result of two general practices in the QRISK2 group 
using Informatica (a software addition that offers some 
JBS3 functionalities), and because heart age and allowing 
manipulation are possible (but not main features) in 
QRISK2.
Discussion of CVD risk factors and risk management
Over one- third of total NHSHC time was spent discussing 
CVD risk factors. This was slightly higher in the QRISK2 
versus JBS3- informed NHSHCs, but with wide variation 
within groups (table 2).
Interventions to manage risk were discussed for 
approximately one- fifth of total consultation time and 
predominantly related to lifestyle, rather than medical 
intervention, which was not discussed at all in over 30% of 
QRISK2 and 42% of JBS3- informed NHSHCs (r=−0.12).
Verbal dominance
Practitioners spoke for just over half of total time in 
QRISK2 consultations and just under half in JBS3 
(figure 2). There was an indication of higher practitioner 
verbal dominance in NHSHC using QRISK2 versus JBS3 
(r=0.27).
DISCUSSION
Main findings
We present the first objective data on the content of 
NHSHC consultations, with comparison of QRISK2 and 
JBS3 CVD risk calculators. Second- by- second coding 
of 173 video- recorded NHSHC consultations from 12 
general practices provided new insights regarding dura-
tion, verbal dominance and allocation of time to different 
components of the consultation. Main findings in rela-
tion to our study aims were as follows. First, the length 
of NHSHC consultations was varied and often short 
(most <20 min). Less than 10% of time (<2 min) was 
spent discussing the individual’s calculated CVD risk, 
and the largest component was discussion of causal CVD 
risk factors. Second, there was evidence of practitioner 
verbal dominance as, on average, practitioners spoke for 
half of total consultation time (compared with ~23% with 
patients speaking). Third, compared with QRISK2, there 
were indications that use of JBS3 was associated with more 
discussion of CVD risk, less discussion of CVD risk factors, 
reduced practitioner verbal dominance and, on average, 
required only 1.4 additional minutes (<90 s).
What this study adds
The variable and often short duration of NHSHC, 
combined with practitioner verbal dominance are a 
potential concern. Sixty per cent of NHSHC in the RICO 
study lasted less than 20 min, 18% less than 15 min and 
4% were under 10 min. Nearly all (95%) had a verbal 
Figure 1 Duration of NHSHC consultation by CVD risk calculator group. HC, Health Check.
7Gidlow CJ, et al. BMJ Open 2020;10:e037790. doi:10.1136/bmjopen-2020-037790
Open access
dominance ratio greater than 1, 57% had a ratio of 2 or 
more, and 36% were over 3, which indicates some degree 
of verbal dominance. Practitioner verbal dominance 
suggests more information provision than the desired 
patient- centred two- way interaction that seeks to under-
stand the patients’ contexts, priorities and preferences, 
to allow appropriate goal- setting. While information 
provision is an important part of the process, the litera-
ture on clinician–patient interactions suggests that short, 
paternalistic primary care consultations are associated 
with low patient and clinician satisfaction.18 This can have 
negative implications for patient outcomes, potentially 
reducing adherence to clinician recommendations, and 
their ability to self- care or make informed decisions about 
their health.15–17
Practitioner–patient interactions are complex.42 The 
practitioner–patient balance has been discussed as a 
spectrum of locus of control, with a paternalistic health 
professional at one end and the informed patient at the 
other.43 The latter requires that control is mutual or 
exchanged, allowing a negotiated plan; in this case, a 
negotiated plan to manage CVD risk. The nature of inter-
actions has been conceptualised and measured variously. 
For example, patient enablement, whereby patients have 
understanding, confidence and coping ability following 
enabling consultations,15 and physician–patient collab-
oration, where both physician and patient are active 
participants in consultations.44 A common feature of 
consultations that foster these beneficial relationships 
(and should lead to better outcomes) is the active partici-
pation of patients in the consultation and decisions about 
their healthcare. Our data indicate that there is scope 
in NHSHC for greater patient participation, especially 
as motivational interviewing should be a key feature of 
NHSHC and relies on a patient- centred approach.25
The length of appointments that practices allocated 
to NHSHC ranged from 15 to 30 min. This showed vari-
ation in the time that general practices were willing to 
give to NHSHC, and the associated time constraints for 
practitioners delivering NHSHC in those practices. Yet, 
video recordings highlighted even greater variability in 
the actual duration of practitioner–patient interaction 
(6.8–38 min). The length of primary care nurse appoint-
ments varies by appointment type. NHSHCs require a 
number of clinical and administrative tasks, such as: CVD 
risk assessment involving measurement of (and entry of 
data for) weight, blood pressure and, sometimes, choles-
terol through point- of- care testing; lifestyle assessment 
(physical activity, alcohol, diet); explaining to patients 
their CVD risk score(s) and what it means; patient- centred 
discussion of risk management to prompt risk- reducing 
behaviours. In light of evidence that shared decision- 
making takes time and techniques like motivational inter-
viewing might require 15 or more min to be effective, it is 
reasonable to suggest that consultations lasting much less 
than 20 min are unlikely to achieve all of the above while 
allowing time for appropriate levels of patient participa-
tion as part of a mutual exchange.
A primary focus of the RICO study was CVD risk 
communication in NHSHC. To promote health- protective 
behaviours that reduce CVD risk, practitioners need to 
understand the risk information and be able to communi-
cate it effectively such that patients leave the consultation 
with the knowledge and intention to act.40 The little time 
Figure 2 Mean percentage of total NHSHC time with speaking by practitioner or patient. NHSHC, NHS Health Check.
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dedicated to CVD risk discussion (<10%), especially when 
using QRISK2, accords with findings from the 2017 system-
atic review of qualitative studies.45 The review authors iden-
tified patients’ ‘limited understanding of the risk score’ as a 
common theme. Some patients reported improved under-
standing of CVD risk following their NHSHC, but many did 
not recall being told their risk, found it confusing or had 
misinterpreted their risk score.
Our data confirmed that nearly all practitioners using 
JBS3 conveyed heart age, healthy years and used risk score 
manipulation (as requested). This appeared to result in a 
slightly higher proportion of total time spent discussing 
CVD risk in JBS3- informed consultations (although not 
reaching significance), but equated to less than one addi-
tional minute, on average. This raises the question of 
whether JBS3 improve patient engagement and under-
standing of their risk, or simply require more information 
provision. That one in three patients in JBS3 consultations 
asked questions about their CVD risk (32%), compared 
with one in eight QRISK2 patients (12%), suggests better 
engagement, but qualitative analysis is required to provide 
a more complete understanding. RICO did not include 
extensive practitioner training in use of JBS3. Rather, an 
introductory briefing with a supporting digital versatile 
disc (DVD) were used to maintain the ecological validity of 
exploring how practitioners would use JBS3 if made avail-
able in practice (not the effect of additional training, which 
is generally not available in practice).46 Such training might 
be required and general CVD risk communication training 
for NHSHC practitioners has shown some benefits for prac-
titioner confidence and understanding.46
The apparent focus on causal risk factors, discussion of 
which comprised 38% of NHSHC time overall (over 40% 
when using QRISK2), is perhaps an indication that practi-
tioners did not spend much time explaining and inviting 
discussion around the risk score(s) and what they mean, 
but focused more on the potential causes and their manage-
ment. This could be interpreted positively as a solution- 
focused approach that focuses on the tangible factors that 
might be easily understood; that is, how their medical 
history and lifestyle can lead and help to prevent CVD. 
However, it is important that this discussion is in the context 
of the patient’s CVD risk and tailored to their lifestyle and 
priorities. Risk communication is challenging.36 If delivered 
effectively, it can enhance knowledge and decision- making 
about treatment, and can empower and create autonomy.47 
Conversely, poor communication of risk can cause patients 
anxiety and reduce confidence in health professionals, or 
may result in the perception that action is futile.48 There-
fore, the 38% and 20% of NHSHC time spent discussing 
CVD risk factors and management, respectively, could be 
undermined if the patient is confused or alarmed by the 
preceding information about their CVD risk.
Implications for practice
The 2019 green paper, Advancing our health: prevention 
in the 2020s, set out plans for an evidence- based review 
of NHSHC to maximise benefit in the next decade.4 
This indicates a future for NHSHC, with evidence- based 
changes to delivery. Despite the importance of risk commu-
nication, associated recommendations in NHSHC’s best 
practice guidance25 and the practitioners’ competence 
framework that includes CVD risk communication,10 
ours are the first objective data showing the varied and 
often short NHSHC, the limited time devoted to CVD risk 
discussion, and the potential for JBS3 to enhance this. We 
know that training in NHSHC is a challenge to optimal 
implementation.13 Practitioners generally receive little 
(or no) training in CVD risk communication for NHSHC 
and can lack the associated confidence and skills.46 Our 
data strengthen the case for NHSHC practitioner training, 
ideally with patient involvement, to redress the practi-
tioner verbal dominance and help to make the discussion 
of CVD risk appropriate and positive for patients. JBS3 
(or similar tools) could form part of this solution.
Strengths and limitations
The strengths of this study include video recording 
of NHSHCs across a diverse range of practices strat-
ified by deprivation, stratified sampling of patients 
and our comprehensive coding framework with excel-
lent inter- rater reliability that offers a methodological 
contribution. A number of limitations are recognised. 
First, challenges with practice and patient recruitment 
meant that we did not achieve our target sample size 
of 240 (120/group). A larger sample size might have 
identified more marked between- group differences 
through increasing the precision of our estimates (ie, 
narrowing CIs). Second, there was a between- group 
difference in mean age. This did not translate into 
a difference in CVD risk, which would have intro-
duced more systematic bias into the sample. But it 
would mean that risk was underestimated in the larger 
proportion of younger people in the QRISK2 group 
(compared with the JBS3 group). Third, these quanti-
tative data do not tell us directly about quality of discus-
sion or exact nature of patients’ response. However, 
the duration of time spent on different elements of 
risk communication and subsequent management 
planning do provide valuable indirect evidence about 
patient engagement, the balance of contributions 
and content within NHSHC consultations. Fourth, 
we cannot claim that our results are generalisable to 
the rest of England. But, we had a good balance of 
men/women, a good age range and proportions of 
WBRI and BAME groups that were appropriate for 
the region. Fifth, after commencing data collection, 
we discovered that two QRISK2 practices used Infor-
matica, an addition to practice software that has some 
of the JBS3 functionalities. To maintain the ecolog-
ical validity of a ‘usual care’ group, the 34 patients 
from these practices were retained, as they will be for 
qualitative analysis. Finally, it is possible that being 
video recorded affected practitioners’ behaviour 
(Hawthorne effect). To mitigate this, our PPIE 
explored camera position to best capture patients’ 
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response and minimise practitioners’ awareness of 
the camera. Practitioners in mock NHSHCs reported 
forgetting about the camera during consultations. 
Moreover, the Hawthorne effect tends to improve 
performance,49 which would lead to an underestimate 
of issues with NHSHC delivery.
CONCLUSIONS
Duration of the practitioner–patient interaction in 
NHSHC is varied and, in many cases, short. Our data 
highlight that little NHSHC time is devoted to discussing 
the patients’ calculated CVD risk, however it does appear 
that JBS3 can support an extended discussion and might 
prompt more patient engagement. The impact of prac-
titioner verbal dominance on patient experience and 
outcomes should be further explored. Public Health 
England’s competence framework for NHSHC speci-
fies the need for NHSHC practitioners to be trained in 
communicating the risk scores and to engage in person- 
centred conversations around risk- reducing behavioural 
changes.10 Although our qualitative findings will provide a 
more complete picture and elucidate the true potential of 
JBS3, our current data support the need for practitioners’ 
training in this area and, potentially, for additions to stan-
dard competencies within health professional training.
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